AlphaStocks
4.9
Weak

Pacira BioSciences, Inc. (PCRX)

Health Care / Pharmaceuticals

S&P SmallCap 600

$25.39

Below average on several measures. Research carefully.

Weak

Score based on 5 of 5 models — high confidence

#582out of 1121 in Health Care

Is Pacira BioSciences, Inc. a Good Investment in 2026?

Pacira BioSciences, Inc. (PCRX) scores 4.9 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates Pacira BioSciences, Inc. as Strong (9/9). However, the Greenblatt Magic Formula model rates it Caution — Bottom half (rank 84%). Pacira BioSciences, Inc. currently trades above its estimated fair value of $13, suggesting limited upside at current prices. Pacira BioSciences, Inc. ranks #582 out of 1121 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E162.6ROE0.7Market Cap1B

Estimated Fair Value

$13.0195% above

Trading above estimated fair value. P/e of 163x implies high growth expectations.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

9/9

Buffett

Attractive

Business quality & competitive moat

Graham

Neutral

Significantly above fair value

Lynch

Neutral

PEG 3.7 · Fast Grower

Greenblatt

Caution

Bottom half (rank 84%)

Frequently Asked Questions

Is Pacira BioSciences, Inc. (PCRX) a good investment?
Based on AlphaStocks' composite analysis, Pacira BioSciences, Inc. (PCRX) scores 4.9 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trading above estimated fair value. P/e of 163x implies high growth expectations.
What is Pacira BioSciences, Inc.'s Piotroski F-Score?
Pacira BioSciences, Inc.'s Piotroski F-Score status is Strong. The raw score is 9/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is PCRX overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $13, PCRX appears overvalued. The stock currently trades 95% above its estimated fair value. Trading above estimated fair value. P/e of 163x implies high growth expectations.
How does PCRX compare to other Health Care stocks?
Pacira BioSciences, Inc. ranks #582 out of 1121 stocks in the Health Care sector, placing it in the top 52% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about PCRX?
AlphaStocks evaluates PCRX using five proven investment models. Piotroski: Strong; Buffett: Attractive; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 4.9/10.

Similar Stocks

PARRBFAMAZN

Compare PCRX with

PCRX vs PARRPCRX vs BFAMPCRX vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer